⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10758480 | 0.77 | — | — | |
| SCHEMBL29590 | 0.71 | — | — | |
| SCHEMBL162387 | 0.71 | — | — | |
| SCHEMBL5059570 | 0.71 | — | — | |
| Urea SCHEMBL28582421 | 0.68 | — | — | |
| SCHEMBL9862949 | 0.67 | — | — | |
| Propionamide SCHEMBL29066899 | 0.67 | TDP1 (0.35) | — | |
| SCHEMBL13733829 | 0.67 | — | — | |
| Carbamic Acid SCHEMBL2144222 | 0.65 | ACHE (0.58) | — | |
| Carbamic Acid SCHEMBL28000124 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146249-A1 | ANTISENSE OLIGONUCLEOTIDES FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH AN ABNORMAL PROCESSING OF APP | VICO THERAPEUTICS B.V. (NL) | 2026-05-28 | — | — | US | disclosed |
| WO-2026099473-A1 | OLIGONUCLEOTIDES WITH NEW INTERNUCLEOSIDE LINKAGE | VICO THERAPEUTICS B.V. (NL) | 2026-05-15 | — | — | WO | disclosed |
| US-20260115665-A1 | ULTRAFILTRATION METHODS | BioSpring Gesellschaft für Biotechnologie mbH (DE) | 2026-04-30 | — | — | US | disclosed |
| EP-4728071-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASE | ProQR Therapeutics II B.V. (NL) | 2026-04-22 | — | — | EP | disclosed |
| EP-4015631-B1 | NOVEL PROCESSES FOR THE PRODUCTION OF OLIGONUCLEOTIDES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2026-02-18 | — | — | EP | disclosed |
| EP-4689107-A1 | CHEMICALLY MODIFIED ANTISENSE OLIGONUCLEOTIDES FOR USE IN RNA EDITING | ProQR Therapeutics II B.V. (NL) | 2026-02-11 | — | — | EP | disclosed |
| EP-4688143-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF LIVER DISEASE | ProQR Therapeutics II B.V. (NL) | 2026-02-11 | — | — | EP | disclosed |
| EP-4689110-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | ProQR Therapeutics II B.V. (NL) | 2026-02-11 | — | — | EP | disclosed |
| EP-4674964-A1 | RNA INTERFERENCE STRATEGIES TARGETING SMALL HEAT SHOCK PROTEIN B8 | Universiteit Antwerpen (BE) | 2026-01-07 | — | — | EP | disclosed |
| US-20250382325-A1 | DEPROTECTION PROCESSES AND CATION SCAVENGERS FOR USE IN THE SAME | EXACTMER LTD (GB) | 2025-12-18 | — | — | US | disclosed |
| US-20140213780-A1 | PROCESS FOR SEPARATION OF OLIGONUCLEOTIDE OF INTEREST FROM A MIXTURE | GLAXO GROUP LIMITED (GB) | 2014-07-31 | — | — | US | disclosed |
| EP-2751283-A1 | PROCESS FOR SEPARATION OF OLIGONUCLEOTIDE OF INTEREST FROM A MIXTURE | Glaxo Group Limited (GB) | 2014-07-09 | — | — | EP | disclosed |
| EP-2699269-A1 | NEW COMPOUNDS FOR TREATING, DELAYING AND/OR PREVENTING A HUMAN GENETIC DISORDER SUCH AS MYOTONIC DYSTROPHY TYPE 1 (DM1) | Prosensa Technologies B.V. (NL) | 2014-02-26 | — | — | EP | disclosed |
| US-20140045763-A1 | COMPOUNDS FOR TREATING, DELAYING AND/OR PREVENTING A HUMAN GENETIC DISORDER SUCH AS MYOTONIC DYSTROPHY TYPE I (DMI) | PROSENSA TECHNOLOGIES B.V. (CH) | 2014-02-13 | — | — | US | disclosed |
| WO-2014011053-A1 | OLIGONUCLEOTIDES FOR MAKING A CHANGE IN THE SEQUENCE OF A TARGET RNA MOLECULE PRESENT IN A LIVING CELL | PROQR THERAPEUTICS B.V. (NL) | 2014-01-16 | — | — | WO | disclosed |
| WO-2014007620-A2 | OLIGONUCLEOTIDE FOR THE TREATMENT OF MUSCULAR DYSTROPHY PATIENTS | PROSENSA TECHNOLOGIES B.V. (NL) | 2014-01-09 | — | — | WO | disclosed |
| WO-2013162363-A1 | RNA modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders | PROSENSA TECHNOLOGIES B.V. (NL) | 2013-10-31 | — | — | WO | disclosed |
| WO-2013112053-A1 | RNA MODULATING OLIGONUCLEOTIDES WITH IMPROVED CHARACTERISTICS FOR THE TREATMENT OF DUCHENNE AND BECKER MUSCULAR DYSTROPHY | PROSENSA TECHNOLOGIES B.V. (NL) | 2013-08-01 | — | — | WO | disclosed |
| WO-2013030263-A1 | PROCESS FOR SEPARATION OF OLIGONUCLEOTIDE OF INTEREST FROM A MIXTURE | GLAXO GROUP LIMITED (GB) | 2013-03-07 | — | — | WO | disclosed |
| WO-2012144906-A1 | NEW COMPOUNDS FOR TREATING, DELAYING AND/OR PREVENTING A HUMAN GENETIC DISORDER SUCH AS MYOTONIC DYSTROPHY TYPE 1 (DM1) | PROSENSA TECHNOLOGIES B.V. (NL) | 2012-10-26 | — | — | WO | disclosed |